Beximco Pharmaceuticals Limited has secured a €24.9 million loan from ODDO BHF SE to expand its production capacity for local and export markets. The loan, confirmed in February, will fund machinery and equipment purchases by December 31. Approved by Bangladesh Investment Development Authority (Bida), it features a 6-month Euribor interest rate plus a 1.3% margin, with repayments starting June 2025 over five years. Previously, Beximco Pharma received a €19.05 million loan from the same bank, fully repaid in January. The company’s recent expansions include Unit-3’s launch in 2021 with Tk1,000 crore investment, alongside acquisitions of Nuvista Pharma and Synovia Pharma. Dominating Bangladesh’s pharmaceutical exports, it reaches 68 markets, with exports contributing 9.4% of total revenue. Analysts predict improved profitability following a 50% drop in Chinese API prices, expecting sector-wide gross profit margin increases. As of March 2024, Bangladesh’s pharmaceutical industry is valued at Tk31,200 crore, with Beximco Pharma holding 9.6% market share and reporting significant revenue and profit growth in FY24.
BIZDATAINSIGHTS
Bizdata Insights is a Market Insights, Data Intelligence and Business Advisory Platform
Our Solutions
Menu
Newsletter
Sign up for our newsletter now by entering your e-mail address and never miss out on the latest news and updates from our team!